CN110366597B - 用蛋白酶抑制剂进行血液图谱分析 - Google Patents

用蛋白酶抑制剂进行血液图谱分析 Download PDF

Info

Publication number
CN110366597B
CN110366597B CN201780087011.XA CN201780087011A CN110366597B CN 110366597 B CN110366597 B CN 110366597B CN 201780087011 A CN201780087011 A CN 201780087011A CN 110366597 B CN110366597 B CN 110366597B
Authority
CN
China
Prior art keywords
proteins
red blood
blood cell
protein
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780087011.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN110366597A (zh
Inventor
本杰明·罗丝·赫伯特
伊丽莎白·卡斯滕
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sangui Bio Pty Ltd
Original Assignee
Sangui Bio Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangui Bio Pty Ltd filed Critical Sangui Bio Pty Ltd
Publication of CN110366597A publication Critical patent/CN110366597A/zh
Application granted granted Critical
Publication of CN110366597B publication Critical patent/CN110366597B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN201780087011.XA 2016-12-20 2017-12-18 用蛋白酶抑制剂进行血液图谱分析 Active CN110366597B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662436875P 2016-12-20 2016-12-20
US62/436,875 2016-12-20
US201762482582P 2017-04-06 2017-04-06
US62/482,582 2017-04-06
US201762523489P 2017-06-22 2017-06-22
US62/523,489 2017-06-22
PCT/AU2017/000282 WO2018112500A1 (en) 2016-12-20 2017-12-18 Blood profiling with protease inhibitors

Publications (2)

Publication Number Publication Date
CN110366597A CN110366597A (zh) 2019-10-22
CN110366597B true CN110366597B (zh) 2024-03-29

Family

ID=62624059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780087011.XA Active CN110366597B (zh) 2016-12-20 2017-12-18 用蛋白酶抑制剂进行血液图谱分析

Country Status (7)

Country Link
US (1) US11693006B2 (cg-RX-API-DMAC7.html)
EP (1) EP3559253A4 (cg-RX-API-DMAC7.html)
JP (2) JP2020502545A (cg-RX-API-DMAC7.html)
CN (1) CN110366597B (cg-RX-API-DMAC7.html)
AU (1) AU2017379367B2 (cg-RX-API-DMAC7.html)
CA (1) CA3047607A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018112500A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1258470A1 (zh) 2015-10-07 2019-11-15 善威生物私人有限公司 血液制备和图谱分析
AU2016374643B2 (en) 2015-12-22 2023-12-14 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
JP2020502545A (ja) 2016-12-20 2020-01-23 サングイ バイオ ピーティーワイ. エルティーディー プロテアーゼインヒビターを用いる血液プロファイリング
CN111999503B (zh) * 2020-05-28 2022-05-20 首都医科大学附属北京地坛医院 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒
US11905249B2 (en) 2021-01-25 2024-02-20 Jackson State University Covalent inhibitors of equine encephalitis virus
US20230358759A1 (en) * 2022-05-04 2023-11-09 Creative Medical Technologies, Inc. Cytokine based assessment of recipient ability to respond to stem cell therapy for cartilage regeneration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795387A (zh) * 2003-03-25 2006-06-28 普罗特奥格尼克斯公司 生物液体的蛋白质组分析
CN1922304A (zh) * 2003-10-31 2007-02-28 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
WO2008134526A2 (en) * 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer
WO2011127056A2 (en) * 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
WO1992005801A1 (en) 1990-10-04 1992-04-16 University Of Virginia Alumni Patents Foundation Primate erythrocyte bound monoclonal antibody heteropolymers
FR2778851B1 (fr) 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
US8431117B2 (en) 1999-08-30 2013-04-30 David S Terman Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
EP1355656A2 (en) 2000-07-24 2003-10-29 Gendel Limited Red blood cell as vehicle for agent-membrane translocation sequence conjugate
ES2498369T3 (es) 2002-04-16 2014-09-24 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Un marcador para medir cirrosis hepática
GB0325483D0 (en) 2003-10-31 2003-12-03 Plasmacute As Assay
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7378054B2 (en) 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
EP1839056B1 (en) * 2004-12-21 2011-08-03 Yale University Diagnosis of preeclampsia
US20060166223A1 (en) 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
WO2006123253A2 (en) 2005-03-29 2006-11-23 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
FR2919804B1 (fr) 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
CN102037355A (zh) 2008-03-04 2011-04-27 里奇诊断学股份有限公司 基于多重生物标记物板块诊断和监测抑郁症
US20110086424A1 (en) 2008-05-06 2011-04-14 Advanced Cell Technology, Inc. Methods for producing enucleated erythroid cells derived from pluripotent stem cells
WO2010147621A1 (en) 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Methods for ameliorating adverse effects associated with transfusion of aged red blood cells
CA2769889A1 (en) 2009-08-13 2011-02-17 Basf Se Means and methods for diagnosing thyroid disorders
WO2011091154A2 (en) 2010-01-21 2011-07-28 The Regents Of The University Of California Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
US20150111238A1 (en) 2011-05-31 2015-04-23 Singapore Health Services Pte. Ltd. Method for detecting disease biomarkers
DK2730650T3 (en) 2011-07-06 2017-04-10 Histocell Sl Method of Treating Mesenchymal Stem Cells and Their Use in Treating Oxidative Stress Diseases
GB201116767D0 (en) 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
US20150086521A1 (en) 2012-03-21 2015-03-26 Erytech Pharma Medicament for the Treatment of Acute Myeloid Leukemia (AML)
HU230341B1 (hu) 2012-04-20 2016-02-29 Advancell Diagnosztika Kft. A vörösvérsejt-membrán kvantitatív biomarkerei
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
CN105228596B (zh) 2013-05-10 2018-08-24 爱瑞德勒股份有限公司 用于制备载有一种或多种制药学感兴趣物质的红细胞的方法和由此得到的红细胞
JP6383920B2 (ja) 2013-09-11 2018-09-05 有限会社ピコデバイス パーキンソン病の判定基準とする方法
KR101845588B1 (ko) 2014-04-07 2018-04-05 한양대학교 산학협력단 적혈구계 세포의 인 비트로 확장
PT3297641T (pt) 2015-05-18 2025-10-09 Hemanext Inc Métodos de armazenamento de sangue total e respetivas composições
HK1258470A1 (zh) 2015-10-07 2019-11-15 善威生物私人有限公司 血液制备和图谱分析
AU2016374643B2 (en) 2015-12-22 2023-12-14 Sangui Bio Pty. Ltd Therapeutic methods using erythrocytes
JP2020502545A (ja) 2016-12-20 2020-01-23 サングイ バイオ ピーティーワイ. エルティーディー プロテアーゼインヒビターを用いる血液プロファイリング

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1795387A (zh) * 2003-03-25 2006-06-28 普罗特奥格尼克斯公司 生物液体的蛋白质组分析
CN1922304A (zh) * 2003-10-31 2007-02-28 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
WO2008134526A2 (en) * 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer
WO2011127056A2 (en) * 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators;Renate B. Schnabel等;《Blood》;20091229;第115卷(第26期);摘要、第5290-5294页方法和结果 *
The effect of protease inhibitors on the two-dimensional electrophoresis pattern of red blood cell membranes;E Olivieri等;Electrophoresis;第22卷(第3期);摘要、材料与方法2.1、第562-563页结果与讨论、图1 *

Also Published As

Publication number Publication date
AU2017379367A1 (en) 2019-07-04
JP7425903B2 (ja) 2024-01-31
EP3559253A1 (en) 2019-10-30
EP3559253A4 (en) 2020-08-26
CN110366597A (zh) 2019-10-22
AU2017379367B2 (en) 2023-12-07
US11693006B2 (en) 2023-07-04
JP2023055749A (ja) 2023-04-18
JP2020502545A (ja) 2020-01-23
WO2018112500A1 (en) 2018-06-28
US20200096512A1 (en) 2020-03-26
CA3047607A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP7425903B2 (ja) プロテアーゼインヒビターを用いる血液プロファイリング
US20240060997A1 (en) Blood Preparation and Profiling
Martinez-Varea et al. Clinical chorioamnionitis at term VII: the amniotic fluid cellular immune response
Blom et al. IL-33 induces IL-9 production in human CD4+ T cells and basophils
De Biasi et al. Endogenous control of inflammation characterizes pregnant women with asymptomatic or paucisymptomatic SARS-CoV-2 infection
JP2021502573A (ja) 末梢動脈疾患、大動脈弁狭窄症についての診断および予後の方法、ならびにアウトカム
Mäkikallio et al. Umbilical artery chemokine CCL16 is associated with preterm preeclampsia and fetal growth restriction
WO2020229691A2 (en) Method for selecting a patient for a reperfusion therapy
JP5648905B2 (ja) 肝臓がん発症の検出又はリスクの予測方法
Farnsworth et al. AACC guidance document on laboratory testing for the assessment of preterm delivery
Toth et al. Case report: Complex evaluation of coagulation, fibrinolysis and inflammatory cytokines in a SARS-CoV-2 infected pregnant woman with fetal loss
Noori et al. Measurement of Homocysteine Levels in Pregnant Women With and Without Preeclampsia
US20240361336A1 (en) Newborn screening for congenital heart defect using cardiovascular biomarkers in dried blood samples
Gurlek et al. Can vitamin D, B12, folic acid, inflammatory markers and H. pylori effective in the process of chronic spontaneous urticaria?
WO2015060779A1 (en) Method for decision support in diagnosis of neutropenic fever in hematology patients
Crowley Neutrophil dynamics in idiopathic pulmonary fibrosis
CN118443940A (zh) Sp70在制备肺癌pd-1/pd-l1阻断治疗疗效预测试剂中的应用
VITAMIN Scientific Abstracts 1109
US20140004540A1 (en) Methods and kits for predicting the risk of having a cardiovascular event in a subject

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant